Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 29, 2018 - The FDA approved Novartis’ Signifor LAR (pasireotide), for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
Return to publications